2026-04-17T14:29:44Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/128842025-05-03T03:20:03Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
Sobrero, Alberto
author
Dasari, Arvind
author
Jeneth Aquino, Jeneth Aquino
author
Elez, Elena
author
Lonardi, Sara
author
Garcia-Carbonero, Rocio
author
Tabernero, Josep
2025-05-03T03:20:03Z
2025-05-03T03:20:03Z
2025-04-02T12:40:35Z2025-04-02T12:40:35Z2025-03-11
http://hdl.handle.net/11351/12884
Fruquintinib; Health-related quality of life; Metastatic colorectal cancerFruquintinib; Calidad de vida relacionada con la salud; Cáncer colorrectal metastásicoFruquintinib; qualitat de vida relacionada amb la salut; Càncer colorectal metastàticIntroduction
Maintaining or improving health-related quality of life (HRQoL) is as important as extending survival in metastatic colorectal cancer. We report an HRQoL analysis from FRESCO-2 (NCT04322539).
Methods
Patients were randomized to fruquintinib +best supportive care (BSC; n = 461) or placebo +BSC (n = 230). Instruments of EORTC QLQ-C30 and 5-level EQ-5D, and ECOG performance status (PS) were assessed. Changes from baseline scores for QLQ-C30 and EQ-5D were evaluated and minimally important difference thresholds were used to define stable, improved, or deteriorated QoL. Time to deterioration (TTD) was assessed.
Results
With fruquintinib versus placebo, baseline QLQ-C30 global health status (GHS) and EQ-5D visual analog scale (VAS) scores were 65.2 versus 64.6 and 67.0 versus 66.6, respectively. Least-squares mean changes from baseline fluctuated throughout treatment. At end of treatment (EOT), mean scores with fruquintinib versus placebo were 53.8 versus 52.3 (QLQ-C30 GHS) and 58.9 versus 58.5 (EQ-5D VAS). For QLQ-C30 GHS, 38.3 % versus 36.5 % of patients receiving fruquintinib versus placebo had stable or improved scores at EOT; median TTD was 2.1 versus 1.8 months (HR, 0.9; 95 % CI, 0.7–1.0). For EQ-5D VAS, 47.9 % versus 42.7 % had stable or improved scores at EOT; median TTD was 2.6 versus 1.9 months (HR, 0.8; 95 % CI, 0.6–0.9). Median TTD to ECOG PS ≥ 2 or death within 30+ /7 days after EOT was 6.6 versus 2.9 months with fruquintinib versus placebo (HR, 0.6; 95 % CI, 0.4–0.7).
Conclusions
Fruquintinib delayed TTD of ECOG PS and did not negatively impact HRQoL versus placebo.This study was funded by HUTCHMED.
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Còlon - Càncer - Tractament
Recte - Càncer - Tractament
Metàstasi
Pacients - Satisfacció
Proteïnes quinases - Inhibidors - Ús terapèutic
CHEMICALS AND DRUGS::Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Tyrosine Kinases
Other subheadings::Other subheadings::Other subheadings::/antagonists & inhibitors
HEALTH CARE::Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
COMPUESTOS QUÍMICOS Y DROGAS::enzimas y coenzimas::enzimas::transferasas::fosfotransferasas::fosfotransferasas (grupo alcohol aceptor)::proteína cinasas::proteína-tirosina cinasas
Otros calificadores::Otros calificadores::Otros calificadores::/antagonistas & inhibidores
ATENCIÓN DE SALUD::ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion